Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Most employers are seeing 8% to 10% increases this cycle, driven primarily by pharmacy costs and GLP-1 utilization
The proportion of psychiatric AEs reported as adverse reactions in patients treated with semaglutide (5.82%) was slightly higher than that in patients treated with other GLP-1 RAs
These costs are recouped through patent protection and premium pricing once the drug is approved and launched on the market
Its no wonder that in May 2022 Tirzapetide got FDA-approved for treating Type 2 Diabetes, and a Fast Track Designation in October 2022 for treating non-diabetic obese adults
For those without insurance, we provide competitive self-pay options, alongside our weight loss medication that's covered by insurance
US$ 25.55
US$ 25.40
US$ 25.56
US$ 24.92
/media/img/mt/2026/07/PeptideGoldRush/original.png){kind=icon}
US$ 28.04
